Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2
   PubMedGoogle Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747–752. doi: 10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Tada K, Kumamaru H, Miyata H, et al. Characteristics of female breast cancer in japan: annual report of the national clinical database in 2018. Breast Cancer. 2023 Mar;30(2):157–166. doi: 10.1007/s12282-022-01423-4
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Aug 1;30(8):1194–1220. doi: 10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• Almeida M, Laurent MR, Dubois V, et al. Estrogens and Androgens in skeletal physiology and pathophysiology. Physiol Rev. 2017 Jan;97(1):135–187. doi: 10.1152/physrev.00033.2015
   PubMed Web of Science ®Google Scholar
• Noirrit-Esclassan E, Valera M-C, Tremollieres F, et al. Critical role of estrogens on bone homeostasis in both male and female: from physiology to medical implications. Int J Mol Sci. 2021;22(4):1568. doi: 10.3390/ijms22041568
   PubMed Web of Science ®Google Scholar
• Hadji P. Cancer treatment-induced bone loss in women with breast cancer. Bonekey Rep. 2015;4:692. doi: 10.1038/bonekey.2015.60
   PubMedGoogle Scholar
• Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncology. 2006 Nov;11(10):1121–1131. doi: 10.1634/theoncologist.11-10-1121
   Google Scholar
• Colzani E, Clements M, Johansson AL, et al. Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br J Cancer. 2016 Nov 22;115(11):1400–1407. doi: 10.1038/bjc.2016.314
   PubMed Web of Science ®Google Scholar
• Becker T, Lipscombe L, Narod S, et al. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc. 2012 Sep;60(9):1761–1767. doi: 10.1111/j.1532-5415.2012.04107.x
   PubMed Web of Science ®Google Scholar
• Ramchand SK, Cheung YM, Yeo B, et al. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019 Jun 1;241(3):R111–r124. doi: 10.1530/joe-19-0077
   PubMed Web of Science ®Google Scholar
• Vestergaard P. Skeletal effects of drugs to treat cancer. Curr Drug Saf. 2008 Sep;3(3):173–177. doi: 10.2174/157488608785699522
   PubMedGoogle Scholar
• Fukumoto S, Soen S, Taguchi T, et al. Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. J Bone Miner Metab. 2020 Mar;38(2):141–144. doi: 10.1007/s00774-020-01087-0
   PubMed Web of Science ®Google Scholar
• Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017 Jun;7:1–12. doi: 10.1016/j.jbo.2017.03.001
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Lacchetti C, Neuner J. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: asco clinical practice guideline summary. J Oncol Pract. 2019;15(12):665–669. doi: 10.1200/jop.19.00427
   Web of Science ®Google Scholar
• Nakatsukasa K, Koyama H, Ouchi Y, et al. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results. Breast Cancer. 2019 Jan;26(1):106–112. doi: 10.1007/s12282-018-0896-y
   PubMed Web of Science ®Google Scholar
• Nakatsukasa K, Koyama H, Ouchi Y, et al. Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study. Ther Clin Risk Manag. 2018;14:1213–1218. doi: 10.2147/tcrm.s167579
   PubMed Web of Science ®Google Scholar
• Nakatsukasa K, Koyama H, Ouchi Y, et al. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab. 2019 Mar;37(2):301–306. doi: 10.1007/s00774-018-0917-0
   PubMed Web of Science ®Google Scholar
• Takahashi S, Iwase T, Kohno N, et al. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat. 2012 Jun;133(2):685–693. doi: 10.1007/s10549-012-1973-0
   PubMed Web of Science ®Google Scholar
• Nakamura M. 1. Utilization of MDV data and data quality control. Japanese J Pharmacoepidemiol. 2016 Aug 31;21(1):23–25. doi: 10.3820/jjpe.21.23
   Google Scholar
• Granger E, Watkins T, Sergeant JC, et al. A review of the use of propensity score diagnostics in papers published in high-ranking medical journals. BMC Med Res Methodol. 2020 May 27;20(1):132. doi: 10.1186/s12874-020-00994-0
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55. doi: 10.1093/biomet/70.1.41
   Web of Science ®Google Scholar
• Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci. 2010 Feb 1;25(1):1–21. doi: 10.1214/09-sts313
   PubMed Web of Science ®Google Scholar
• Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016 Feb 9;133(6):601–609. doi: 10.1161/circulationaha.115.017719
   PubMed Web of Science ®Google Scholar
• Noordzij M, Leffondré K, van Stralen KJ, et al. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. 2013 Nov;28(11):2670–2677. doi: 10.1093/ndt/gft355
   PubMed Web of Science ®Google Scholar
• Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011 Sep 7;103(17):1299–1309. doi: 10.1093/jnci/djr242
   PubMedGoogle Scholar
• International Agency for Research on Cancer. GLOBOCAN fact sheet Japan. Geneva: WHO; 2020.
   Google Scholar
• Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002 Jun 22;359(9324):2131–2139. doi: 10.1016/s0140-6736(02)09088-8
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747–2757. doi: 10.1056/NEJMoa052258
   PubMed Web of Science ®Google Scholar
• van de Velde CJH, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011 Jan 22;377(9762):321–331. doi: 10.1016/S0140-6736(10)62312-4
   PubMed Web of Science ®Google Scholar
• Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res. 2006 Aug;21(8):1215–1223. doi: 10.1359/jbmr.060508
   PubMed Web of Science ®Google Scholar
• Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008 Mar 1;26(7):1051–1057. doi: 10.1200/jco.2007.11.0726
   PubMed Web of Science ®Google Scholar
• Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009 Sep;20(9):1489–1498. doi: 10.1093/annonc/mdp033
   PubMed Web of Science ®Google Scholar
• Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol. 2009 Jul;20(7):1203–1209. doi: 10.1093/annonc/mdn762
   PubMed Web of Science ®Google Scholar
• Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol. 2007 Feb;8(2):119–127. doi: 10.1016/s1470-2045(07)70003-7
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005 Aug 6-12;366(9484):455–462. doi: 10.1016/s0140-6736(05)67059-6
   PubMed Web of Science ®Google Scholar
• Aihara T, Takatsuka Y, Ohsumi S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat. 2010 Jun;121(2):379–387. doi: 10.1007/s10549-010-0888-x
   PubMed Web of Science ®Google Scholar
• Boccardo F, Guglielmini P, Bordonaro R, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23(22):5138–5147. doi: 10.1200/JCO.2005.04.120
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010 Dec;11(12):1135–1141. doi: 10.1016/S1470-2045(10)70257-6
   PubMed Web of Science ®Google Scholar
• Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol. 2011 Apr;22(4):857–862. doi: 10.1093/annonc/mdq541
   PubMed Web of Science ®Google Scholar
• Ruhstaller T, Giobbie-Hurder A, Colleoni M, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 2019 Jan 10;37(2):105–114. doi: 10.1200/JCO.18.00440
   PubMed Web of Science ®Google Scholar
• Morden JP, Alvarez I, Bertelli G, et al. Long term follow-up of the intergroup exemestane study (IES). J Clin Oncol. 2017 Aug 1;35(22):2507–2514. doi: 10.1200/JCO.2016.70.5640
   PubMed Web of Science ®Google Scholar
• Derks MGM, Blok EJ, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1211–1220. doi: 10.1016/S1470-2045(17)30419-9
   PubMed Web of Science ®Google Scholar
• Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010 Feb 20;28(6):967–975. doi: 10.1200/JCO.2009.24.5902
   PubMed Web of Science ®Google Scholar
• Monda V, Lupoli GA, Messina G, et al. Improvement of bone physiology and life quality due to association of risedronate and anastrozole. Front Pharmacol. 2017 Sep 12;8:632. doi: 10.3389/fphar.2017.00632
   PubMed Web of Science ®Google Scholar
• Confavreux CB, Fontana A, Guastalla JP, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone. 2007 Sep;41(3):346–352. doi: 10.1016/j.bone.2007.06.004
   PubMed Web of Science ®Google Scholar
• Yonehara Y, Iwamoto I, Kosha S, et al. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. J Obstet Gynaecol Res. 2007 Oct;33(5):696–699. doi: 10.1111/j.1447-0756.2007.00634.x
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 Aug 1;386(9992):433–443. doi: 10.1016/S0140-6736(15)60995-3
   PubMed Web of Science ®Google Scholar
• Nakatsukasa K, Koyama H, Ouchi Y. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Bone Miner Metab. 2018 Nov;36(6):716–722. doi: 10.1007/s00774-017-0884-x
   PubMed Web of Science ®Google Scholar
• Soen S, Kaku M, Okubo N, et al. Fracture risk associated with glucocorticoid-induced osteoporosis in Japan. J Bone Miner Metab. 2022 Jul;40(4):636–647. doi: 10.1007/s00774-022-01325-7
   PubMed Web of Science ®Google Scholar
• Kirigaya D, Nakayama T, Ishizaki T, et al. Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adherence to clinical guidelines and related factors. Intern Med. 2011;50(22):2793–2800. doi: 10.2169/internalmedicine.50.5266
   PubMed Web of Science ®Google Scholar
• Soen S, Kaku M, Okubo N, et al. Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan. J Bone Miner Metab. 2021 Nov;39(6):1019–1030. doi: 10.1007/s00774-021-01236-z
   PubMed Web of Science ®Google Scholar
• Bao Y, Xu Y, Li Z, et al. Racial and ethnic difference in the risk of fractures in the United States: a systematic review and meta-analysis. Sci Rep. 2023 Jun 10;13(1):9481. doi: 10.1038/s41598-023-32776-1
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with different types of cancer. Acta Oncol. 2009;48(1):105–115. doi: 10.1080/02841860802167490
   PubMed Web of Science ®Google Scholar
• Ye C, Leslie WD. Fracture risk and assessment in adults with cancer. Osteoporos Int. 2023 Mar;34(3):449–466. doi: 10.1007/s00198-022-06631-4
   PubMed Web of Science ®Google Scholar
• Gong IY, Chan KKW, Lipscombe LL, et al. Fracture risk among patients with cancer compared to individuals without cancer: a population-based study. Br J Cancer. 2023 Sep;129(4):665–671. doi: 10.1007/s00774-021-01236-z
   PubMed Web of Science ®Google Scholar
• Shimoi T, Nagai SE, Yoshinami T, et al. The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer. 2020 May;27(3):322–331. doi: 10.1007/s12282-020-01085-0
   PubMed Web of Science ®Google Scholar